Richard Pazdur

61.6k total citations · 16 hit papers
596 papers, 37.7k citations indexed

About

Richard Pazdur is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Richard Pazdur has authored 596 papers receiving a total of 37.7k indexed citations (citations by other indexed papers that have themselves been cited), including 332 papers in Oncology, 214 papers in Pulmonary and Respiratory Medicine and 116 papers in Cancer Research. Recurrent topics in Richard Pazdur's work include Colorectal Cancer Treatments and Studies (122 papers), Cancer Treatment and Pharmacology (90 papers) and Lung Cancer Treatments and Mutations (86 papers). Richard Pazdur is often cited by papers focused on Colorectal Cancer Treatments and Studies (122 papers), Cancer Treatment and Pharmacology (90 papers) and Lung Cancer Treatments and Mutations (86 papers). Richard Pazdur collaborates with scholars based in United States, Canada and Thailand. Richard Pazdur's co-authors include Patricia Keegan, Martin H. Cohen, Rajeshwari Sridhara, Ann T. Farrell, Robert Justice, John R. Johnson, Gideon M. Blumenthal, Steven J. Lemery, Julia A. Beaver and Kirsten B. Goldberg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Richard Pazdur

578 papers receiving 36.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

2007 1.1k citations John R. Johnson, Martin H. Cohen et al. The Oncologist profile →
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

2019 789 citations Steven J. Lemery, Richard Pazdur et al. Clinical Cancer Research profile →
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 660 citations Richard Pazdur et al. profile →
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

2018 610 citations Robert Q. Le, Liang Li et al. The Oncologist profile →
Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration

2004 547 citations Richard Pazdur et al. profile →
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

2003 505 citations Robert C. Kane, Ann T. Farrell et al. The Oncologist profile →
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

2017 457 citations Steven J. Lemery, Richard Pazdur et al. profile →
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

2007 407 citations Brian Booth, Shenghui Tang et al. Clinical Cancer Research profile →
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

2016 337 citations Daniel L. Suzman, Gideon M. Blumenthal et al. The Oncologist profile →
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

2021 330 citations Lola A. Fashoyin‐Aje, Martha Donoghue et al. Clinical Cancer Research profile →
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

2016 285 citations Gideon M. Blumenthal, Richard Pazdur et al. The Oncologist profile →
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →
FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

2021 193 citations Nicole Drezner, Pallavi S. Mishra‐Kalyani et al. Clinical Cancer Research profile →
The Drug-Dosing Conundrum in Oncology — When Less Is More

2021 180 citations Marc R. Theoret, Richard Pazdur et al. profile →
Trends in the approval of cancer therapies by the FDA in the twenty-first century

2023 155 citations Yutao Gong, Richard Pazdur et al. profile →
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

2022 127 citations Sundeep Agrawal, Sriram Subramaniam et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Richard Pazdur

Since Specialization

Citations

This map shows the geographic impact of Richard Pazdur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Pazdur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Pazdur more than expected).

Fields of papers citing papers by Richard Pazdur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Pazdur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Pazdur. The network helps show where Richard Pazdur may publish in the future.

Co-authorship network of co-authors of Richard Pazdur

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Pazdur. A scholar is included among the top collaborators of Richard Pazdur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Pazdur. Richard Pazdur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation 2025 ·Clinical Cancer Research ·Ashley Woods, Dianne Pulte, (unknown), Jonathon Vallejo, (unknown), (unknown), Javier G. Blanco, Sarah E. Dorff, Hongshan Li, (unknown), Ólanrewaju O. Okusanya, Richard Pazdur, Marc R. Theoret, R. Angelo de Claro, Kelly J. Norsworthy	1
2	FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD 2025 ·Clinical Cancer Research ·Kelly J. Norsworthy, Donna R. Rivera, Joseph Wynne, Jian Zhao, (unknown), (unknown), Jonathon Vallejo, (unknown), Ólanrewaju O. Okusanya, Brian Booth, Paul G. Kluetz, Richard Pazdur, R. Angelo de Claro	0
3	FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib 2021 ·The Oncologist ·May Tun Saung, Lorraine Pelosof, Sandra J. Casak, Martha Donoghue, Steven J. Lemery, Mengdie Yuan, Lisa Rodríguez, (unknown), Meredith K. Chuk, (unknown), Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola A. Fashoyin‐Aje	77
4	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation 2021 ·Clinical Cancer Research ·Dianne Pulte, Kelly J. Norsworthy, Yaping Wang, (unknown), Hisham Qosa, Ramadevi Gudi, Donna Przepiorka, Wentao Fu, Ólanrewaju O. Okusanya, Kirsten B. Goldberg, R. Angelo de Claro, Ann T. Farrell, Richard Pazdur	57
5	FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review 2021 ·Clinical Cancer Research ·(unknown), Paz J. Vellanki, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Huiming Xia, Yangbing Li, Jiang Liu, Jeanne Fourie Zirkelbach, (unknown), (unknown), Qiuyi Choo, (unknown), Ulrich‐Peter Rohr, (unknown), Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh	42
6	The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology 2021 ·Clinical Cancer Research ·Julie A. Schneider, Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani, Julia A. Beaver, Lola A. Fashoyin‐Aje, Nicole Gormley, (unknown), Steven J. Lemery, Pallavi S. Mishra‐Kalyani, Gregory H. Reaman, Donna R. Rivera, Wendy S. Rubinstein, Harpreet Singh, Rajeshwari Sridhara, Richard Pazdur	1
7	Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy 2020 ·The Oncologist ·Lorraine Pelosof, May Tun Saung, Martha Donoghue, Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Xiling Jiang, Jiang Liu, Hong Zhao, (unknown), Kirsten B. Goldberg, Marc R. Theoret, Steven J. Lemery, Richard Pazdur, Lola A. Fashoyin‐Aje	9
8	An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer 2020 ·Clinical Cancer Research ·Michael H. Brave, Chana Weinstock, Jamie R. Brewer, (unknown), Daniel L. Suzman, Joyce Cheng, Lijun Zhang, Rajeshwari Sridhara, Amna Ibrahim, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver	20
9	FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia 2019 ·Clinical Cancer Research ·Kelly J. Norsworthy, Kunthel By, Sriram Subramaniam, Luning Zhuang, Pedro L. Del Valle, Donna Przepiorka, Yuan Li Shen, Christopher M. Sheth, Chao Liu, Rupert W. Leong, Kirsten B. Goldberg, Ann T. Farrell, Richard Pazdur	93
10	FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation 2019 ·Clinical Cancer Research ·Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E. Dorff, Donna Przepiorka, Albert Deisseroth, Yuan Li Shen, Christopher M. Sheth, Rosane Charlab, Gene M. Williams, Kirsten B. Goldberg, Ann T. Farrell, Richard Pazdur	102
11	FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome 2019 ·Clinical Cancer Research ·Yvette L. Kasamon, Haiyan Chen, R. Angelo de Claro, Lei Nie, Jingjing Ye, Gideon M. Blumenthal, Ann T. Farrell, Richard Pazdur	51
12	FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia breakdown → 2018 ·Clinical Cancer Research ·Aviva C. Krauss, Xin Gao, Liang Li, Michael L. Manning, Paresma Patel, Wentao Fu, Kumar G. Janoria, Gerlie Gieser, David A. Bateman, Donna Przepiorka, Yuan Li Shen, Stacy S. Shord, Christopher M. Sheth, Anamitro Banerjee, Jiang Liu, Kirsten B. Goldberg, Ann T. Farrell, Gideon M. Blumenthal, Richard Pazdur	252
13	FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia 2018 ·Clinical Cancer Research ·Maura O’Leary, Xiaobin Lü, Ying Huang, Xue Lin, Iftekhar Mahmood, Donna Przepiorka, Denise Gavin, Shiowjen Lee, Ke Liu, Bindu George, Wilson W. Bryan, Marc R. Theoret, Richard Pazdur	221
14	FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease 2018 ·Clinical Cancer Research ·Emily Y. Jen, (unknown), Aaron J. Schetter, Donna Przepiorka, Yuan Li Shen, Donna Roscoe, Rajeshwari Sridhara, Albert Deisseroth, Reena Philip, Ann T. Farrell, Richard Pazdur	98
15	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy 2018 ·The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, (unknown), V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, (unknown), Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver	138
16	FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome breakdown → 2018 ·The Oncologist ·Robert Q. Le, Liang Li, Weishi Yuan, Stacy S. Shord, Lei Nie, Bahru Habtemariam, Donna Przepiorka, Ann T. Farrell, Richard Pazdur	610
17	An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies 2016 ·Clinical Cancer Research ·Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur, Reena Philip	26
18	FDA Approval: Blinatumomab 2015 ·Clinical Cancer Research ·Donna Przepiorka, Chia‐Wen Ko, Albert Deisseroth, Carolyn L. Yancey, (unknown), Haw-Jyh Chiu, Brenda J. Gehrke, (unknown), Robert C. Kane, Susan Kirshner, Nitin Mehrotra, Tiffany K. Ricks, Deborah H. Schmiel, Pengfei Song, Ping Zhao, Qing Zhou, Ann T. Farrell, Richard Pazdur	261
19	Rare Cancer Trial Design: Lessons from FDA Approvals 2012 ·Clinical Cancer Research ·(unknown), Ke Liu, Anne Pariser, Richard Pazdur	49
20	Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors 2012 ·The Oncologist ·Martin H. Cohen, John R. Johnson, Robert Justice, Richard Pazdur	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact